College of Fisheries, Southwest University, Chongqing, China.
Key Laboratory of Freshwater Fish Reproduction and Development (Ministry of Education), College of Life Sciences, Southwest University, Chongqing, China.
Microbiol Spectr. 2021 Dec 22;9(3):e0148721. doi: 10.1128/Spectrum.01487-21. Epub 2021 Nov 24.
Viral diseases of the central nervous system (CNS) represent a major global health concern. Difficulties in treating these diseases are caused mainly by the biological tissues and barriers, which hinder the transport of drugs into the CNS. To counter this, a nanobody-mediated virus-targeting drug delivery platform (SWCNTs-P-A-Nb) is constructed for CNS viral disease therapy. Viral encephalopathy and retinopathy (VER), caused by nervous necrosis virus (NNV), is employed as a disease model. SWCNTs-P-A-Nb is successfully constructed by employing single-walled carbon nanotubes, amantadine, and NNV-specific nanobody (NNV-Nb) as the nanocarrier, anti-NNV drug, and targeting ligand, respectively. Results showed that SWCNTs-P-A-Nb has a good NNV-targeting ability and , improving the specific distribution of amantadine in NNV-infected sites under the guidance of NNV-Nb. SWCNTs-P-F-A-Nb can pass through the muscle and gill and be excreted by the kidney. SWCNTs-P-A-Nb can transport amantadine in a fast manner and prolong the action time, improving the anti-NNV activity of amantadine. Results so far have indicated that the nanobody-mediated NNV-targeting drug delivery platform is an effective method for VER therapy, providing new ideas and technologies for control of the CNS viral diseases. CNS viral diseases have resulted in many deadly epidemics throughout history and continue to pose one of the greatest threats to public health. Drug therapy remains challenging due to the complex structure and relative impermeability of the biological tissues and barriers. Therefore, development in the intelligent drug delivery platform is highly desired for CNS viral disease therapy. In the study, a nanobody-mediated virus-targeting drug delivery platform is constructed to explore the potential application of targeted therapy in CNS viral diseases. Our findings hold great promise for the application of targeted drug delivery in CNS viral disease therapy.
中枢神经系统（CNS）的病毒疾病是一个主要的全球健康关注点。这些疾病的治疗困难主要是由于生物组织和屏障的存在，它们阻碍了药物进入 CNS 的运输。为了解决这个问题，构建了一种纳米体介导的病毒靶向药物传递平台（SWCNTs-P-A-Nb）用于治疗中枢神经系统病毒疾病。神经坏死病毒（NNV）引起的病毒性脑炎和视网膜病变（VER）被用作疾病模型。通过使用单壁碳纳米管、金刚烷胺和 NNV 特异性纳米体（NNV-Nb）作为纳米载体、抗 NNV 药物和靶向配体，成功构建了 SWCNTs-P-A-Nb。结果表明，SWCNTs-P-A-Nb 具有良好的 NNV 靶向能力，在 NNV-Nb 的指导下，提高了金刚烷胺在 NNV 感染部位的特异性分布。SWCNTs-P-F-A-Nb 可以穿过肌肉和鳃，并通过肾脏排泄。SWCNTs-P-A-Nb 可以快速运输金刚烷胺并延长作用时间，提高金刚烷胺的抗 NNV 活性。到目前为止的结果表明，纳米体介导的 NNV 靶向药物传递平台是治疗 VER 的有效方法，为 CNS 病毒疾病的治疗提供了新的思路和技术。中枢神经系统病毒疾病在历史上导致了许多致命的流行病，仍然是对公众健康的最大威胁之一。由于生物组织和屏障的复杂结构和相对不可渗透性，药物治疗仍然具有挑战性。因此，开发智能药物传递平台对于中枢神经系统病毒疾病的治疗非常重要。在本研究中，构建了一种纳米体介导的病毒靶向药物传递平台，以探索靶向治疗在中枢神经系统病毒疾病中的潜在应用。我们的研究结果为靶向药物输送在中枢神经系统病毒疾病治疗中的应用提供了重要依据。
